ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Sevilla, AN, ESP:

Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer. (TRIFOUR)

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) wo ...

Enrolling
Triple Negative Breast Cancer
Drug: Carboplatin
Drug: Nadunolimab

Phase 1, Phase 2

Cantargia

Sevilla, Andalucía, Spain and 23 other locations

Triple-negative breast cancer (TNBC) is a group of tumors that occurs mainly in young, premenopausal wom ...

Enrolling
Triple-negative Breast Cancer
Drug: Pembrolizumab 25 mg/ml
Drug: Paclitaxel injection

Phase 2

Unicancer
Unicancer

Sevilla, Spain and 43 other locations

in patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC), refractory to ...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Sacituzumab govitecan
Drug: Granulocyte Colony-Stimulating Factor

Phase 2

MedSIR

Sevilla, Spain and 9 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Sevilla, Spain and 228 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Sevilla, Spain and 516 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Active, not recruiting
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Sevilla, Spain and 108 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Sevilla, Spain and 505 other locations

to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...

Enrolling
Triple-Negative Breast Cancer
Biological: sac-TMT
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Sevilla, Andalucia, Spain and 117 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Sevilla, Spain and 192 other locations

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Sevilla, Spain and 140 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems